|
 |
|
BIBLIOGRAFIA
 ESTUDIO MULTICÉNTRICO SOBRE LA EFICACIA MOVILIZADOTA DEL FILGRASTIM (G-CSF) EN LA OBTENCIÓN DE CÉLULAS CD34+ EN PACIENTES (PTS) CON CÁNCER DE MAMA PREVIAMENTE TRATADAS CON QUIMIOTERAPIA.
Hornedo, J.; Solà, C.; Solano, C.; López, JJ.; Lluch, A.;, García-Conde, J.; Cortés-Funes, H.
XXXVII Reunión Nacional de la Asociación Española de Hematología y Hemoterapia. Zaragoza, 2-4 de Noviembre de 1995.
|
MULTICENTER STUDY ON THE EFFICACY OF FILGRASTIM IN OBTAINING CD34+ CELLS IN BREAST CANCER PATIENTS (PTS) PREVIOUSLY TREATED WITH CHEMOTHERAPY.
Hornedo, J.; Solà, C.; Solano, C.; López, JJ.; Lluch, A.;, García-Conde, J.; Cortés-Funes, H.
37th Annual Meeting of the ASH. Seattel, 1-5, Diciembre 1995.
|
HIGH DOSE CHEMOTHERAPY (HDCT) AND AUTOLOGOUS PERIPHERAL ÍTEM-CELL TRANSPLANTATION 8APSCT) ALTER NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED (LABC) AND INFLAMMATORY BREAST CANCER.
García-Conde, J.; Cortés-Funes, H.; Hornedo, Lluch, A.;J.; C.; López-López, J.J.; Azagra, P.; Solano, C.; Solà, C..
21st Congress European Society for Medical Oncology. Viena (Austria), 1-5, Noviembre 1996.
|
HIGH DOSE CHEMOTHERAPY (HDCT) AND AUTOLOGOUS PERIPHERAL SÍTEM-CELL TRANSPLANTATION (APSCT) AFTER STANDARD CHEMOTHERAPY (CT) IN HIGH-RISK BREAST CANCER PATIENTS (≥ 10 AXILLIARY NODE INVOLVEMENT AFTER SURGERY).
García-Conde J, Sola C, Solano C, Azaga P, Hornedo J, Cortés-Funes H, López JJ, Lluch A.
Thirty-Two Annual Meeting American Society of Clinical Oncology, 1996.
|
HIGH DOSE CHEMOTHERAPY (HDCT) AND AUTOLOGOUS PERIPHERAL SÍTEM-CELL TRANSPLANTATION (APSCT) AFTER STANDARD CHEMOTHERAPY (CT) IN HIGH-RISK BREAST CANCER PATIENTS (GREATER THAN OR EQUAL TO 10 AXILLIARY NODE INVOLVEMENT AFTER SURGERY).
García-Conde, J.; Cortés-Funes, H.; Hornedo, Lluch, A.; López-López, J.J.; Azagra, P.; Solano, C.; Solà, C.
Thirty-Two Annual Meeting American Society of Clinical Oncology, 1996.
|
MULTICENTER, PROSPECTIVE, RANDOMIZED STUDY OF THE ROLE OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) IN THE PROSTRANSPLANT PERIOD FOLLOWING HIGH-DOSE CHEMOTHERAPY 8HDC), SUPPORTED WITH G-CSF-MOBILIZED, PERIPHERAL BLOOD ÍTEM CELLS PBSC), IN BREAST CANCER PATIENTS (PTS).
Hornedo, J.; Solà, C.; Solano, C.; Lluch, A.; Benavides, M.; López, J.J.; García-Conde, J.; Cortés-Funes, H.
21st Congress European Society for Medical Oncology. Viena (Austria), 1-5, Noviembre 1996.
|
THE ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) IN THE POST-TRANSPLANT PERIOD. RESULTS OF A MULITCENTER, RANDOMIZED TRIAL IN BREAST CANCER (BC) PATIENTS (PTS) TREATED WITH HIGH-DOSE CHEMOTHERAPY AND C-CSF MOBILIZED, PERIPHERAL BLOOD STEM CELLS AUTOLOGOUS TRANSPLANTATION (PBSCT): EVIDENCE OF A SHORTENING IN THE HOSPITALIZATION TIME.
Hornedo, J.; Solà, C.; Solano, C.; Lluch, A.; García-Conde, J.; et. al.
Thirty-Fourth Annual Meeting American Society of Clinical Oncology. Los Angeles, 16-19 Mayo 1998.
|
PHASE II STUDY OF WEEKLY PACLITAXEL (P) IN RECURRENT BREAST CANCER ALTER HIGH-DOSE CHEMOTHERAPY (HDC).
Solà, D.; Lluch, A.; García-Conde, J.; Solano, C.; García, T.; et. al.
Thirty-Fourth Annual Meeting American Society of Clinical Oncology. Los Angeles, 16-19 Mayo 1998.
|
OUTCOME OF EXTENSIVE EVALUATION EEFOTE HIGH-DOSE CHEMOTHERAPY (HDC) IN PATIENTS (PTS) WITH HIGH-RISK.
López-López, J.J.; Lluch, A.; Solà, C.; Hornedo, J.; Climent, M.A.; Montes, A.;, Benavides, M.; Vera, R.; Cruz Hernández, J.; Alvarez, I.; Montesinos, J.; Salazar, R.; Prosper, F.; Alonso, S.; García-Conde.
J Breast Cancer (BC). Abstr.223: J. Clin. Oncol. American Society of Clinical Oncology (Asco). 35th Annual Meeting. Atlanta, 15-18 Mayo 1999.
|
PHASE II STUDY OF WEEKLY PACLITAXEL (P) TREATMENT IN RECURRENT BREAST CANCER ALTER HIGH-DOSE CHEMOTHERAPY (HDC) .
Solà, D.; Lluch, A.; García-Conde, J.; Salazar, R.; García, T.; Montesinos, J.; Vera, R.; Benavides, M.; Climent, M.A.; Hornedo, J.; Alvarez, I.; Prosper, F.; Cortés-Funes, H.; López-López, J.J.; Solti Group.
Abstr. 245 J. Clin. Oncol. American Society of Clinical Oncology (Asco). 35th Annual Meeting. Atlanta, 15-18 Mayo 1999
|
HIGH DOSE CHEMOTHERAPY (HDC) AND STEM CELL TRANSPLANT (SCT) FOR HIGH RISK BREAST CANCER (HRBC): RESULTS OF 235 TRANSPLANTS.
Lluch, A.; Solà, C.; Hornedo, J.; Germà, J.R.; Benavides, M.; Baselga, J.; Guillén, V.; Cruz, J.J.; Alvarez, I.; Mayordomo, J.I.; Prosper, F.; Ojeda, B.; Alonso, S.; Cortés-Funes, H.; López, J.J.; García-Conde, J.
Abstr 303 J. Clin. Oncol. American Society of Clinical Oncology (Asco). 35th Annual Meeting. Atlanta, 15-18 Mayo 1999.
|
PHASE II STUDY OF WEEKLY PACLITAXEL (P) TREATMENT IN RECURRENT BREAST CANCER AFTER HIGH-DOSE CHEMOTHERAPY (HDC).
Sola C, Lluch A, García-Conde J, Salñazar R, García T, Montesinos J, Vera R, Benavides M, Climent MA, Hornedo J, Alvarez I, Prósper F, Cortés-Funes H, López-López JJ. SOLTI group Spain.
Proceedings ASCO 1999; 18:65a.
|
HIGH-DOSE CHEMOTHERAPY (CT) WIHT PERIPHERAL STEM-CELL (PSCS) SEEMS TO IMPROVE DISEASE-FREE SURVIVAL (DFS) IN INFLAMMATORY BREAST CANCER (IBC) COMPARED WITH AN HISTORICAL SERIES OF PATIENTS (PTS).
Climent, M.A.; Solà, C.; Lluch, A.; Ruix, A.; Hornedo, J.; Benavides, M.; Montes, A.; Baselga, J.; López-López, J.; García-Conde,J.
Abs.548 American Society of Clinical Oncology (ASCO). 36th Annual Meeting. New Orleans, May 20-23.
|
PROGNOSTIC FACTORS FOR RELAPSED ALTER HIGH DOSE CHEMOTHERAPY (HDC) AND STEM CELL TRANSPLANT (SCT) IN PATIENTS WITH HIGH RISK BREAST CANCER (HRBC).
Prosper, F.; Solà, C.; Hornedo, J.; Climent, M.A.; Montes, A.; Benavides, M.; Baselga, J.; Mayordomo, J.I.; Alvarez, I.; López, J.J.; Cortés-Funes, H.; García-Conde, J.
Abs.581 American Society of Clinical Oncology (ASCO). 36th Annual Meeting. New Orleans, May 20-23.
|
THE ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) IN THE POST-TRANSPLANT PERIOD.
Hornedo, J.; Solà, C.; Solano, C.; López, J.J.; Alonso, S.; Lluch, A.; Ojeda, Bl; García- Conde, J.; Cortés-Funes, H.
Bone Marrow Transplantation 2002; 29: 737-743.
|
MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS WITH A COMBINATION OF CYCLOPHOSPHAMIDE, R-METHUSCF AND FILGRASTIM IN PATIENTS WITH BREAST CANCER PREVIOUSLY TREATED WITH CHEMOTHERAPY.
Prosper, F.; Solà, C.; Hornedo, J.; Arbona, C.; Menéndez, P.; Orfao, A.; Lluch, A.; Cortés-Funes, H.; López, J.J.; García-Conde, J.
Leukemia 2003; 17: 437-441.
|
CARDIAC SAFETY AND ACTIVITY OF A PHASE I STUDY OF 3-WEEKLY MYOCET® IN COMBINATION WITH WEEKLY HERCEPTIN® AND PACLITAXEL IN HER2-POSITIVE (HER2+) LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC).
JM Trigo, MA Climent, M Gil, A Lluch, J Hornedo, P Gascón, V Guillem, P Regueiro, J Baselga on behalf of SOLTI Group.
Abst. 242 ASCO Annual Meeting 2002.
|
LIPOSOMAL DOXORUBICIN (MYOCET®) IN COMBINATION WITH HERCEPTIN® AND PACLITAXEL, IS ACTIVE AND WELL TOLERATED IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC): A PHASE II STUDY.
Trigo JM, Climent MA, Lluch A, Gascón P, Hornedo J, Gil M, Cirera L, Guillem V, Regueiro P, Baselga J.
Abst. 351 Breast Cancer Res Treat 2003; S82, S83.
|
CARDIAC SAFETY AND EFFICACY FROM A PHASE I/II TRIAL OF THE LIPOSOMAL DOXORUBICIN MYOCET® IN COMBINATION WITH TRASTUZUMAB (HERCEPTIN®) AND PACLITAXEL IN PATIENTS WITH HHER2-POSITIVE (HER2+) LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC).
JM Trigo, MA Climent, M Gil, A Lluch, J Hornedo, P Gascón, V Guillem, P Regueiro, J Baselga.
EBCC, 2003 Poster.
|
RESULTS OF A PHASE II STUDY OF LIPOSOMAL DOXORUBICIN (MYOCET®) IN COMBINATION WITH WEEKLY PACLITAXEL AND TRASTUZUMAB (HERCEPTIN®) IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC).
J Baselga, MA Climent, A Lluch, J Hornedo, P Gascón, H Cortés-Funes, AT Sánchez, V Guillem, P Regueiro, J Trigo, on behalf of the SOLTI group.
Abs. 262 4th EBCC 2004. EJC 2004; 2: 132.
|
UPDATED RESULTS OF A PHASE II STUDY (M77035) OF MYOCET® COMBINED WITH WEEKLY HERCEPTIN® AND PACLITAXEL IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LABC/MBC)..
Cortés J,1 Climent MA,2 Lluch A,3 Hornedo J,4 Gascón P,5 Mayordomo J,6 Gil M,7 Benavides M,8 Regueiro P,9 Trigo J,1 Baselga J.1 on behalf of the Solti Group..
Abs 3041 27th Annual San Antonio Breast Cancer Symposium, 2004
|
A PHASE I TRIAL OF WEEKLY COMBINATION KOS-862 (EPOTHILONE D) AND TRASTUZUMAB IN HER-2 OVEREXPRESSING MALIGNANCIES..
Cortés, J, Climent M, Gómez P, Ruiz A, Calvo E, Zhang X, Pérez ES, DeMario M, Baselga J.
Abs 2028 ASCO Annual Meeting, 2006.
|
NEOADJUVANT TRASTUZUMAB IN LOCALLY ADVANCED BREAST CANCER (NOAH):ANTITUMOR AND
SAFETY ANALYSIS .
L. Gianni,, et al.
Abs 532 ASCO Annual Meeting, 2007-08-07.
|
EVALUATION OF THE FEASIBILITY, SAFETY AND ANTITUMOURS EFFECTS OF NEOADJUVANT TRASTUZUMAB IN LOCALLY ADVANCED BREAST CANCER (NOAH TRIAL).
J. Baselga, et al.
ASCO Breast Symposium, 2007
|
EFFICACY OF NEOADJUVANT TRASTUZUMAB IN PATIENTS WITH INFLAMMATORY BREAST CANCER: DATA FROM NOAH (NEOANJUVANT HERCEPTIN) PHASE III TRIAL..
J. Baselga, et al.
ECCO 14, 2007
|
KEEPING FAITH WITH TRIAL VOLUNTEERS..
Piccart M, Goldhirsch A, Wood W, Pritchard K, Baselga J, Reaby L, Kossler I, Kyriakides S, Norton L, Coates A.
Nature. 2007; 446: 137-8
|
2-YEAR FOLLOW-UP OF TRASTUZUMAB AFTER ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE BREAST CANCER: A RANDOMISED CONTROLLED TRIAL..
Smith I, Procter M, Gelber RD, et al. On behalf HERA study team
Lancet. 2007; 369:29-36
|
MULTICENTRIC PHASE II TRIAL OF GEMCITABINE PLUS CAPECITABINE COMBINATION IN THE TREATMENT OF PREVIOUSLY ANTHRACYCLINE(AN)-TREATED METASTATIC BREAST CANCER (MBC): SOLTI 0301 STUDY..
EM. Ciruelos, J Baselga, H Cortés-Funes, A Lluch, JI Mayordomo, B Ojeda, E. González, M. Muñoz, C Rodríguez, J Cortés. SOLTI Group, Spain. Abstract - No.
1051 ASCO Annual Meeting, 2007
|
PHASE II DOUBLE-BLIND RANDOMIZED TRIAL OF DAILY ORAL RAD001 (EVEROLIMUS) PLUS LETROZOLE (LET) OR PLACEBO (P) PLUS LET AS NEOADJUVANT THERAPY FOR ER+ BREAST CANCER.
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Dixon JM, Jonat W, Rugo HS.. Hospital Vall d´Hebron, Barcelona, Spain; NN Petrov Research Inst of Oncology, St. Petersburg, Russian Federation; Onc Centrum St Augustinus, Wilrijk, Belgium; City Oncological Dispensary, St. Petersburg, Russian Federation; Hospital Clinico Univ Lozana Blesa, Zaragoza, Spain; Centre Rene Gauducheau, Nantes, France; General Hospital, Vienna, Austria; Univ Hospital, Salzburg, Austria; Novartis Pharma AG, Basel, Switzerland; Istituto Nazionale Tumori, Milan, Italy; Western General Hospital, Edinburgh, United Kingdom; Univ-Frauenklinik, Kiel, Germany; Univ of CA SF, San Francisco, CA.
POSTER 2066 SABCS 2007
|
BIOMARKER ANALYSIS OF A PHASE II DOUBLE-BLIND RANDOMIZED TRIAL OF DAILY ORAL RAD001 (EVEROLIMUS) PLUS LETROZOLE OR PLACEBO PLUS LETROZOLE AS NEOADJUVANT THERAPY FOR PATIENTS WITH ESTROGEN RECEPTOR POSITIVE BREAST CANCER.
Gardner H, Bandaru R, Barrett C, Calcaterra M, Crowell T, Decker J, Dixon M, Fisch R, Fuchs M, Gelb A, Hanoteau N, Jonat W, Lane H, Lebwohl D, Liu W-H, Molloy B, Pena C, Phillips P, Rheinhardt J, Rugo H, Salesky S, Steinseifer J, Stumm M, Tokaji E, Voelker F, Yarbrough G, Yateman N, Yu Y, Zuber E, Baselga J.. Novartis Institutes for Biomedical Research, Cambridge, MA; Novartis Pharmaceuticals, East Hanover, NJ; Hospital Vall d´Hebron, Barcelona, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Univ-Frauenklinik, Kiel, Germany; UCSF, San Francisco; Western General Hospital, Edinburgh, United Kingdom.
POSTER 4006 SABCS 2007
|
ESTIMATING THE MAGNITUDE OF TRASTUZUMAB EFFECTS WITHIN PATIENT SUBGROUPS IN THE HERA TRIAL.
Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team.
Ann Oncol. 2008 Jun;19(6):1090-6
|
TRASTUZUMAB AFTER ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE BREAST CANCER.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med. 2005 Oct 20;353(16):1659-72.
|
BIBLIOGRAFIA COMENTADA
PRESENTACIONES
|
|
|
